Exclusive Summary

• - US and EU27 registrations validate high compliance, enabling rapid entry via reliance/abridged pathways and efficient Distribution partnerships.
• - IV azithromycin covers atypical pathogens (Legionella, Mycoplasma, Chlamydia) and is used for inpatient CAP and PID initial therapy, sustaining stable hospital demand.
• - Lower respiratory infections have hundreds of millions of episodes and ~2.4–2.7 million deaths annually, driving continuous procurement of IV antibiotics.
• - Fully off‑patent with mature generic competition; typical 70–90% discount versus originator supports tender wins and market penetration.
• - Robust dossier and cGMP track record (US/EU) can be leveraged across GCC, LATAM, Africa and other reliance markets to shorten time-to-market.